In the News
Welcome to our news archive, your resource for company announcements, press releases, and media coverage. Here you’ll find updates on our latest initiatives, strategic partnerships, and industry contributions, as well as background materials to support media inquiries. Explore past stories to see how we continue to shape conversations across healthcare and life sciences.
The FDA is attempting to shut down the black market for retatrutide, a pipeline treatment for obesity, type 2 diabetes and kidney and liver diseases that is still in final-phase testing. Investor’s Business Daily spoke to MMIT’s CCO Jayne Hornung about the black market, the drug’s potential for morbidly obese patients, and what’s likely to happen after FDA approval.
The success of the TrumpRx platform depends in large part on pharmacies’ willingness to accept lower reimbursement rates for drugs they’ve already purchased. MMIT’s Steve Callahan explained that as the program grows, pharmacies might reconsider their business model to ensure they can meet their own margins.
In an effort to reduce healthcare costs, the FDA would like many prescription medications to become over-the-counter products. MMIT’s Steve Callahan explains that while this move would theoretically improve patient access, patients would be responsible for the full cost of these treatments.
A popular asthma medication, Xolair, was selected in the third cycle of the MDPNP—despite the fact that a competing biosimilar will launch before the negotiation period ends. Bloomberg Law taps MMIT’s Steve Callahan for his insights on the drug selection process and the biosimilar pipeline.
PharmaVoice tapped MMIT’s Madeline Verbeke and Evaluate’s Mark Lansdell for insights on market forces in 2026. Madeline addresses the obesity market’s expansion with the growth of oral and combination drugs, while Mark highlights expectations for high-value U.S. pharma / Chinese biotech deals in 2026.
This article from Drug Discovery & Development highlights the market’s strong M&A momentum and a surging Chinese deal landscape, featuring quotes from Evaluate’s Ben Folwell and Mark Lansdell. MMIT’s Madeline Verbeke shares her insights on obesity therapeutics, as new oral drugs are expected to capture meaningful market share.